Literature DB >> 8287600

Expression of high-affinity IL-4 receptors on human melanoma, ovarian and breast carcinoma cells.

N I Obiri1, J P Siegel, F Varricchio, R K Puri.   

Abstract

It has previously been shown that murine sarcoma cells express high-affinity IL-4 receptors (IL-4R) which are internalized after binding to the ligand (Puri et al., Cancer Res 1991; 51:3011-7). We have also reported that human renal cell carcinoma cells express high-affinity IL-4R, and IL-4 inhibits tumour growth in vitro (Obiri et al., J Clin Invest 1993; 91:88). In this study we investigated the expression and function of IL-4R on other human solid tumours. Human melanoma, ovarian carcinoma and breast carcinoma cell lines were assessed for the cell surface expression of IL-4R by radio-ligand receptor binding and for IL-4R gene expression by Northern blot analysis. Primary cultures of mesothelioma and neurofibrosarcoma cells were similarly investigated. Human melanoma, ovarian carcinoma and breast carcinoma cell lines expressed IL-4R on their cell surface with a dissociation constant (Kd) of 140-549 pM. These tumour lines expressed a single 4 kb species of mRNA for IL-4R. Similarly, primary cultures of mesothelioma and neurofibrosarcoma cells were positive for the IL-4R mRNA by Northern blot analysis. Fresh, non-cultured mesothelioma and neurofibrosarcoma tumour sections were also positive for the presence of IL-4R as determined by immunohistochemistry of frozen sections using anti-IL-4R antibody. In order to study possible functions of IL-4R, we evaluated the effects of IL-4 on cell growth and its effect on MHC antigen expression in the presence or absence of interferon-gamma (IFN-gamma). In tissue culture, IL-4 reduced the growth of tumour cell lines and primary cell cultures studied. IL-4 had very little effect on MHC class I antigen expression on ovarian, breast and melanoma cell lines; however, MHC class II (HLA-DR) expression was enhanced on melanoma and breast carcinoma cells. IL-4 also enhanced the IFN-gamma-induced class II expression on melanoma and breast carcinoma cells. Taken together, our observations indicate that IL-4R are expressed on a variety of human solid tumours and these receptors may be functional. IL-4 alone and in combination with IFN-gamma may play a role in host immune response against cancers.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8287600      PMCID: PMC1534619          DOI: 10.1111/j.1365-2249.1994.tb06029.x

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  47 in total

1.  Secretion of IgG1 induction factor by T cell clones and hybridomas.

Authors:  P Sideras; S Bergstedt-Lindqvist; H R MacDonald; E Severinson
Journal:  Eur J Immunol       Date:  1985-06       Impact factor: 5.532

2.  The human thymus microenvironment: heterogeneity detected by monoclonal anti-epithelial cell antibodies.

Authors:  R A de Maagd; W A MacKenzie; H J Schuurman; M A Ritter; K M Price; R Broekhuizen; L Kater
Journal:  Immunology       Date:  1985-04       Impact factor: 7.397

3.  Rapid colorimetric assay for cell viability: application to the quantitation of cytotoxic and growth inhibitory lymphokines.

Authors:  L M Green; J L Reade; C F Ware
Journal:  J Immunol Methods       Date:  1984-05-25       Impact factor: 2.303

4.  Identification of a T cell-derived b cell growth factor distinct from interleukin 2.

Authors:  M Howard; J Farrar; M Hilfiker; B Johnson; K Takatsu; T Hamaoka; W E Paul
Journal:  J Exp Med       Date:  1982-03-01       Impact factor: 14.307

5.  Low doses of IL-4 injected perilymphatically in tumor-bearing mice inhibit the growth of poorly and apparently nonimmunogenic tumors and induce a tumor-specific immune memory.

Authors:  M Bosco; M Giovarelli; M Forni; A Modesti; S Scarpa; L Masuelli; G Forni
Journal:  J Immunol       Date:  1990-11-01       Impact factor: 5.422

6.  Interleukin-4 downregulates interleukin-6 production in human peripheral blood mononuclear cells.

Authors:  J D Lee; S G Swisher; E H Minehart; W H McBride; J S Economou
Journal:  J Leukoc Biol       Date:  1990-05       Impact factor: 4.962

7.  Two types of murine helper T cell clone. I. Definition according to profiles of lymphokine activities and secreted proteins.

Authors:  T R Mosmann; H Cherwinski; M W Bond; M A Giedlin; R L Coffman
Journal:  J Immunol       Date:  1986-04-01       Impact factor: 5.422

8.  Identification of a T helper cell-derived lymphokine that activates resting T lymphocytes.

Authors:  C Milanese; N E Richardson; E L Reinherz
Journal:  Science       Date:  1986-03-07       Impact factor: 47.728

9.  Resistance of human ovarian cancer cells to tumor necrosis factor and lymphokine-activated killer cells: correlation with expression of HER2/neu oncogenes.

Authors:  A Lichtenstein; J Berenson; J F Gera; K Waldburger; O Martinez-Maza; J S Berek
Journal:  Cancer Res       Date:  1990-11-15       Impact factor: 12.701

10.  Interleukin-induced increase in Ia expression by normal mouse B cells.

Authors:  N W Roehm; H J Leibson; A Zlotnik; J Kappler; P Marrack; J C Cambier
Journal:  J Exp Med       Date:  1984-09-01       Impact factor: 14.307

View more
  37 in total

Review 1.  The functions of cytokines and their uses in toxicology.

Authors:  J R Foster
Journal:  Int J Exp Pathol       Date:  2001-06       Impact factor: 1.925

2.  Epithelial interleukin-4 receptor expression promotes colon tumor growth.

Authors:  Felicitas L Koller; Daniel G Hwang; E A Dozier; Barbara Fingleton
Journal:  Carcinogenesis       Date:  2010-02-22       Impact factor: 4.944

3.  Interleukin-4 receptor expression on AIDS-associated Kaposi's sarcoma cells and their targeting by a chimeric protein comprised of circularly permuted interleukin-4 and Pseudomonas exotoxin.

Authors:  S R Husain; P Gill; R J Kreitman; I Pastan; R K Puri
Journal:  Mol Med       Date:  1997-05       Impact factor: 6.354

4.  Toward a new generation of vaccines: the anti-cytokine therapeutic vaccines.

Authors:  D Zagury; A Burny; R C Gallo
Journal:  Proc Natl Acad Sci U S A       Date:  2001-07-03       Impact factor: 11.205

5.  Significant association of the cytokine variants with head and neck cancer risk: evidence from meta-analysis.

Authors:  Ting-Ting Xiao; Xian Li; Ying Xu; Yong Li
Journal:  Eur Arch Otorhinolaryngol       Date:  2017-11-28       Impact factor: 2.503

6.  Localization of IL-4 and IL-4 receptors in the human term placenta, decidua and amniochorionic membranes.

Authors:  M I de Moraes-Pinto; G S Vince; B F Flanagan; C A Hart; P M Johnson
Journal:  Immunology       Date:  1997-01       Impact factor: 7.397

Review 7.  Engineering Biomaterial-Drug Conjugates for Local and Sustained Chemotherapeutic Delivery.

Authors:  Jeannine M Coburn; David L Kaplan
Journal:  Bioconjug Chem       Date:  2015-03-02       Impact factor: 4.774

Review 8.  Targeting IL4/IL4R for the treatment of epithelial cancer metastasis.

Authors:  Katherine Venmar Bankaitis; Barbara Fingleton
Journal:  Clin Exp Metastasis       Date:  2015-09-18       Impact factor: 5.150

9.  A novel reduced immunogenicity bispecific targeted toxin simultaneously recognizing human epidermal growth factor and interleukin-4 receptors in a mouse model of metastatic breast carcinoma.

Authors:  Seunguk Oh; Brad J Stish; Deepali Sachdev; Hua Chen; Arkadiusz Z Dudek; Daniel A Vallera
Journal:  Clin Cancer Res       Date:  2009-09-29       Impact factor: 12.531

Review 10.  Challenges in clinical design of immunotherapy trials for malignant glioma.

Authors:  Cleo E Rolle; Sadhak Sengupta; Maciej S Lesniak
Journal:  Neurosurg Clin N Am       Date:  2010-01       Impact factor: 2.509

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.